Lv4
410 积分 2023-11-27 加入
Effectiveness and safety of tenofovir amibufenamide and its comparison with tenofovir alafenamide in patients with chronic hepatitis B: results from a retrospective real-world study
4天前
已完结
Effects of tenofovir amibufenamide and entecavir on estimated glomerular filtration rate in treatment-naïve patients with chronic hepatitis B
1个月前
已完结
Comparison of HBeAg clearance rates between tenofovir alafenamide and entecavir in treatment-naive HBeAg positive chronic hepatitis B patients over 48 to 96 weeks: A retrospective cohort study
1个月前
已关闭
KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD)
2个月前
已完结
KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)
2个月前
已完结
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
2个月前
已完结
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
3个月前
已完结
Impact of PC/BCP Mutations on Seroconversion and Relapse in HBeAg-Positive Chronic Hepatitis B Patients Treated with Nucleoside Analogues
4个月前
已完结
Comparative efficacy and safety of tenofovir amibufenamide vs tenofovir alafenamide in the initial 48-week treatment of high viral load chronic hepatitis B: A single-centre retrospective study
4个月前
已完结
Tenofovir amibufenamide in chronic hepatitis B: Lipid changes and 144-week safety with tenofovir disoproxil fumarate-to-tenofovir amibufenamide switch
4个月前
已关闭
皖公网安备34019202002308
